The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Inferior survival in Black AML patients treated with intensive chemo is independent of cytogenetics
In this press briefing, Shella Saint Fleur-Lominy, MD, PhD, University of Maryland School of Medicine, Baltimore, MD, presents an ECOG-ACRIN clinical trial analysis examining racial differences in cytogenetic risk, molecular prognostic impact, and survival outcomes in adults with acute myeloid leukemia (AML). This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
